Par Pharmaceuticals (NYSE: PRX) completed its third generics deal in six months with the $20.5 million acquisition of a drug developer and manufacturer based in India.
Edict Pharmaceuticals has 11 abbreviated new drug applications filed with the U.S. Food and Drug Administration.
In November, Par Pharmaceuticals completed its $410 million deal to acquire Anchen Pharmaceuticals, a privately-held company focused on developing and commercializing extended release and niche generic products.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In October the Woodcliff Lake, New Jersey based company acquired the rights to three products from Teva Pharmaceuticals (NASDAQ: TEVA) in connection with Teva’s $6.8 billion acquisition of Cephalon: fentanyl citrate lozenges, a generic version of Actiq – used to treat sudden episodes of pain in cancer patients; cyclobenzaprine ER capsules, the generic version of Amrix – a muscle relaxant used to ease pain; and modafinil tablets, the generic version of Provigil – used to treat excess sleepiness caused by narcolepsy.
